|
Chronic Lymphocytic Leukemia
|
0.800 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway.
|
19098429 |
2008 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
CLL with the 17p deletion or TP53 mutation showed very low miR-34a expression.
|
19643983 |
2009 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Chronic lymphocytic leukemia (CLL) with 17p deletion or mutations of the TP53 gene has a very poor outcome.
|
23188619 |
2013 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
B-chronic lymphocytic leukemia (B-CLL) patients harboring p53 mutations are invariably refractory to therapies based on purine analogues and have limited treatment options and poor survival.
|
25544776 |
2015 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
Chronic lymphocytic leukemia (CLL) is extremely rare in Asian countries and there has been one report on genetic changes for 5 genes (TP53, SF3B1, NOTCH1, MYD88, and BIRC3) by Sanger sequencing in Chinese CLL.
|
27959900 |
2016 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes.
|
28888994 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
TP53 is located at chromosome band 17p13 and its absence can be detected by fluorescence in situ hybridization (FISH) in the interphase nuclei of 8-10% patients with B-CLL.
|
16737921 |
2006 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
TP53 is mutated in 10-20% of cases of chronic lymphocytic leukaemia (CLL) and 3-8% of cases of acute myeloid leukaemia (AML).
|
18341636 |
2008 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations are associated with impaired response and shorter survival in patients with CLL.
|
21483000 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
TP53 abnormalities play a central role in our current understanding of the poor prognosis of high-risk CLL patients, but fail to explain the molecular basis of 50% of high-risk CLL.
|
23216591 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
TP53 abnormalities are common and, as for chronic lymphocytic leukemia, these patients should generally be managed using an alemtuzumab-based therapy.
|
23233647 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutation/deletion is uncommon in chronic lymphocytic leukemia (CLL).
|
24559316 |
2014 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
TP53 mutated and associated del17p states substantially lower response rates, remission duration, and survival in CLL.
|
27040699 |
2016 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes.
|
27270786 |
2016 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutation was present in 81% of del(17p) CLL, mostly clonal (82%), and clonal mutations with del(17p) exhibit shorter overall survival than subclonal mutations with del(17p) (P = 0.019).
|
27503198 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations predominate in IG-unmutated CLL, whereas the opposite is seen for MYD88 mutations, enriched in IG-mutated CLL) and in subsets of cases with stereotyped IG (enrichment for SF3B1 mutations in CLL subset #2).
|
28892161 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
TP53 pathway defects contributed to therapy resistance and adverse clinical outcome in chronic lymphocytic leukemia (CLL), which represents an unmet clinical need with few therapeutic options.
|
29895969 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population
|
31128065 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutation is an indicator of poor prognostic in chronic lymphocytic leukemia (CLL).
|
31226417 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A p53 mutation was found in 16 of 107 (15%) AML, 20 of 182 (11%) MDS, and 9 of 81 (11%) CLL tested.
|
7949187 |
1994 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
A major revolution in the treatment of chronic lymphocytic leukemia (CLL) began with the approval of ibrutinib, a first-in-class oral inhibitor of Bruton tyrosine kinase (BTK), for the treatment of relapsed/refractory (R/R) and/or TP53 mutated patients with CLL.
|
31732977 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
SomaticCausalMutation
|
disease |
ORPHANET |
A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome.
|
21205967 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
Biomarker
|
disease |
BEFREE |
A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome.
|
21205967 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A new genetic abnormality leading to TP53 gene deletion in chronic lymphocytic leukaemia.
|
22150335 |
2012 |